Breaking News

Retrophin Appoints R&D VP

May 30, 2014

Shih oversee all medical, clinical and research functions

Alvin Shih, M.D. has been appointed executive vice president of R&D at Retrophin. Dr. Shih will oversee all medical, clinical and research functions. He joins the company from Pfizer, where he served as chief operating officer of the Rare Disease Research Unit, responsible for strategic initiatives and operational functions of the Unit.
 
Dr. Shih previously served as senior engagement manager for L.E.K. Consulting, LLC, where he provided strategic counsel on M&A transactions and growth development to life sciences companies.
 
 “I am delighted to welcome Alvin to the Retrophin team in this very important leadership position,” said Martin Shkreli, founder and chief executive officer of Retrophin. “His rare disease R&D experience and business acumen will be invaluable as we continue to advance and grow our pipeline of drugs for patients suffering from serious diseases that currently have no viable treatment options.”

blog comments powered by Disqus
  • Newsmakers: PCI

    Newsmakers: PCI

    Tim Wright, Editor||June 2, 2015
    PCI execs talk about the recent opening of the company’s new North American clinical facility, as well as other trends in the market

  • How Sterilization of Primary Packaging Influences the Results of E&L Studies

    How Sterilization of Primary Packaging Influences the Results of E&L Studies

    Thorsten Sogding, Daniel Canton, Daniel Haines, Uwe Rothhaar, SCHOTT Pharma Services ||June 2, 2015
    As the demands that are being placed on the quality and stability of medications continue to increase, the interactions that take place between the primary packaging container and filled drug product are becoming increasingly important

  • Moore’s Law for More Health

    Moore’s Law for More Health

    Patrick Jordan , Encore Health Resources||June 2, 2015
    This year marks the semicentennial anniversary of a prediction about exponential growth and productivity